Ivosidenib and vorasidenib were both evaluated in a surgical window-of-opportunity trial in patients with recurrent non-enhancing grade 2 (43 patients) and 3 (6 patients) IDH1-mt gliomas.143 Two doses of vorasidenib and ivosidenib were used. This evidence concerns the gene IDH1 and central nervous system cancer.